Praluent

Active Ingredient(s): Alirocumab
FDA Approved: * July 24, 2015
Pharm Company: * SANOFI AVENTIS
Category: Cholesterol

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Praluent Overview

Alirocumab (trade name Praluent)[1] is a biopharmaceutical drug approved by the FDA on July 24, 2015 as a second line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials...

Read more Praluent Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alirocumab

Recent Praluent Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Praluent: (4 results)

Sorted by National Drug Code

• 0024-5901 Praluent 75 mg/ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
• 0024-5902 Praluent 150 mg/ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
• 0024-5903 Praluent 75 mg/ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
• 0024-5904 Praluent 150 mg/ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC

Other drugs which contain Alirocumab or a similar ingredient: (1 result)

• ALIROCUMAB